Celltrion Healthcare Canada Limited — licence 3-002622, currently licensed, last inspection rating C (2025-11-12).
No Canadian shortage report is currently matched to this DIN.
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02350106 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | TOCILIZUMAB 200 MG | Marketed |
| 02350114 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | TOCILIZUMAB 400 MG | Marketed |
| 02424770 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02483327 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02350092 | ACTEMRA | HOFFMANN-LA ROCHE LIMITED | Solution | TOCILIZUMAB 80 MG | Marketed |
| 02562022 | AVTOZMA | CELLTRION INC. | Solution | TOCILIZUMAB 80 MG | Marketed |
| 02562057 | AVTOZMA | CELLTRION INC. | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02562030 | AVTOZMA | CELLTRION INC. | Solution | TOCILIZUMAB 200 MG | Marketed |
| 02562065 | AVTOZMA | CELLTRION INC. | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02552450 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | TOCILIZUMAB 80 MG | Marketed |
| 02552477 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | TOCILIZUMAB 400 MG | Marketed |
| 02552485 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02552493 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | TOCILIZUMAB 162 MG | Marketed |
| 02552469 | TYENNE | FRESENIUS KABI CANADA LTD | Solution | TOCILIZUMAB 200 MG | Marketed |